Study to Assess the Efficacy and Safety of Ublituximab + TGR-1202 With or Without Bendamustine and TGR-1202 Alone in Patients With Previously Treated Non-Hodgkins Lymphoma
Trial Status: Active
Unity NHL - A Phase 2b Randomized Study to Assess the Efficacy and Safety of the Combination of Ublituximab + TGR-1202 with or without Bendamustine and TGR-1202 alone in Patients with Previously Treated Non-Hodgkin's Lymphoma
Inclusion Criteria
- Diagnosis of Non-Hodgkin's Lymphoma including Diffuse Large B-cell Lymphoma, Follicular, Mantle Cell Lymphoma and Marginal Zone Lymphoma
- Relapsed or refractory to prior standard therapy and subjects who are not candidates for high-dose therapy or autologous stem cell transplant
- Eastern Cooperative Oncology Group (ECOG) score of 0 to 2
Exclusion Criteria
- Any major surgery, chemotherapy or immunotherapy within the last 21 days
- Evidence of hepatitis B virus, hepatitis C virus or known HIV infection
- Autologous hematologic stem cell transplant within 6 months of study entry. Prior Allogeneic hematologic stem cell transplant is excluded
- Prior therapy with a PI3K delta inhibitor
Arizona
Tucson
Banner University Medical Center - Tucson
Status: ACTIVE
California
Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Status: ACTIVE
Contact: Rosa Bishop
Phone: 310-267-5426
Email:
rbishop@mednet.ucla.edu
Orange
UC Irvine Health / Chao Family Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
San Diego
University of California San Diego
Status: CLOSED_TO_ACCRUAL
Contact: Januario Enrique Castro
Phone: 858-822-5354
Email:
cancercto@ucsd.edu
District of Columbia
Washington
MedStar Georgetown University Hospital
Status: ACTIVE
Florida
Jacksonville
Mayo Clinic in Florida
Status: ACTIVE
Tampa
Moffitt Cancer Center
Status: ACTIVE
Contact: Julio C. Chavez
Phone: 813-745-2069
Email:
Julio.C.Chavez@moffitt.org
Illinois
Chicago
University of Chicago Comprehensive Cancer Center
Status: ACTIVE
Kansas
Kansas City
University of Kansas Cancer Center
Status: ACTIVE
Overland Park
University of Kansas Cancer Center-Overland Park
Status: ACTIVE
Westwood
University of Kansas Hospital-Westwood Cancer Center
Status: ACTIVE
Maryland
Baltimore
University of Maryland / Greenebaum Cancer Center
Status: ACTIVE
Contact: Nicole M. Glynn-Cunningham
Phone: 410-328-7996
Email:
nglynn@umm.edu
Towson
UM Saint Joseph Medical Center
Status: ACTIVE
Michigan
Ann Arbor
University of Michigan Comprehensive Cancer Center
Status: ACTIVE
Missouri
Kansas City
University of Kansas Cancer Center - North
Status: ACTIVE
Lee's Summit
University of Kansas Cancer Center - Lee's Summit
Status: ACTIVE
New Hampshire
Lebanon
Dartmouth Hitchcock Medical Center
Status: ACTIVE
New Jersey
Hackensack
Hackensack University Medical Center
Status: ACTIVE
New York
Bronx
Montefiore Medical Center-Einstein Campus
Status: COMPLETED
Buffalo
Roswell Park Cancer Institute
Status: ADMINISTRATIVELY_COMPLETE
New York
NYP / Columbia University Medical Center / Herbert Irving Comprehensive Cancer Center
Status: CLOSED_TO_ACCRUAL
Ohio
Cleveland
Case Comprehensive Cancer Center
Status: ACTIVE
Pennsylvania
Philadelphia
University of Pennsylvania / Abramson Cancer Center
Status: ACTIVE
Texas
Dallas
UT Southwestern / Simmons Cancer Center-Dallas
Status: CLOSED_TO_ACCRUAL
Contact: Marcella West Aguilar
Phone: 214-648-1479
Email:
SCCCCTRP@UTSouthwestern.edu
Houston
M D Anderson Cancer Center
Status: CLOSED_TO_ACCRUAL
Washington
Seattle
Fred Hutch / University of Washington Cancer Consortium
Status: ACTIVE
Wisconsin
Madison
University of Wisconsin Hospital and Clinics
Status: ACTIVE
Trial Phase Phase II/III
Trial Type Treatment
Lead Organization
TG Therapeutics Inc
- Primary ID UTX-TGR-205
- Secondary IDs NCI-2016-01433
- Clinicaltrials.gov ID NCT02793583